A Guide to Long-Acting Injectables and Implantables
Long-acting products, such as Long-Acting Injectables (LAIs) and implantables, have gained significant traction in recent years, revolutionizing patient treatment and medication adherence. By reducing the number of doses required, long-acting products improve patient compliance and eliminate the risk of missed doses. Moreover, they minimize toxicity and side effects, offering a more comfortable patient experience. This article delves into the numerous benefits of long-acting drug delivery systems, including their ability to harness highly potent APIs, streamline development and intellectual property protection, and provide consistent drug release over extended periods. You’ll explore their applications in various medical fields, such as CNS disorders, cancers, diabetes, substance abuse, eye diseases, HIV treatment and prevention, and contraception. Discover how Lubrizol Life Science – Health overcomes challenges in developing these innovative drug delivery systems and gain insights into successful long-acting drug development. Whether you’re a healthcare professional, researcher, or simply curious about the future of medicine, this article offers valuable knowledge and opens up new possibilities in patient care.
Flexible-Dose Development Strategies for Today's Clinical Landscape - Executive Summary
January 8th 2025This executive summary focuses on dose-flexible manufacturing strategies and their role in drug development. Dose flexibility is increasingly important for early clinical studies, particularly in areas such as pediatric medicines and oncology. However, flexible dosing strategies are often neglected or not prioritized early in development. This presentation will focus on technical strategies that can help anticipate appropriate timing for implementation and how to do so cost effectively while adhering to required timelines.
Molecular Properties of PROTACs and the Relationship to Formulation Design
December 20th 2024Analyzation of a diverse set of PROTAC (Proteolysis Targeting Chimeras – a class of TPDs) structures and their calculated properties, identifying key structure-property trends that contribute to low oral bioavailability.
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.
